These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35757417)

  • 41. The regulation of the follicular synchronization and sensitivity of rats with PCOS by AMH during prolonged pituitary downregulation.
    Huang J; Ding Y; Li Z
    Gene; 2019 Dec; 721():144106. PubMed ID: 31499126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
    Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes.
    Cela V; Obino MER; Alberga Y; Pinelli S; Sergiampietri C; Casarosa E; Simi G; Papini F; Artini PG
    Gynecol Endocrinol; 2018 Jun; 34(6):518-523. PubMed ID: 29271274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of basal luteinizing hormone (bLH) level on in vitro fertilization/intra-cytoplasmic injections (IVF/ICSI) outcomes in polycystic ovarian syndrome (PCOS) patients.
    Liu Z; Wang KH
    BMC Pregnancy Childbirth; 2023 Aug; 23(1):618. PubMed ID: 37644399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of dyslipidemia on IVF/ICSI pregnancy outcome in patients with polycystic ovary syndrome].
    Li X; Ding W; Liu JY; Mao YD; Huang J; Wang W; Ma X
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):402-408. PubMed ID: 29961283
    [No Abstract]   [Full Text] [Related]  

  • 48. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
    Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
    Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
    J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI.
    Sun B; Ma Y; Li L; Hu L; Wang F; Zhang Y; Dai S; Sun Y
    Front Endocrinol (Lausanne); 2020; 11():615957. PubMed ID: 33542709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
    Zhang F; Liu XL; Rong N; Huang XW
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal cutoff value of basal anti-mullerian hormone in iranian infertile women for prediction of ovarian hyper-stimulation syndrome and poor response to stimulation.
    Aghssa MM; Tarafdari AM; Tehraninejad ES; Ezzati M; Bagheri M; Panahi Z; Mahdavi S; Abbasi M
    Reprod Health; 2015 Sep; 12():85. PubMed ID: 26357853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is early-follicular long-acting GnRH agonist protocol an alternative for patients with polycystic ovary syndrome undergoing in vitro fertilization?
    Wang D; Chu T; Yu T; Zhai J
    Reprod Biol Endocrinol; 2022 Sep; 20(1):137. PubMed ID: 36088329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis.
    Wang M; Huang R; Liang X; Mao Y; Shi W; Li Q
    Reprod Biol Endocrinol; 2022 Aug; 20(1):114. PubMed ID: 35941630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
    Ozelci R; Dilbaz S; Dilbaz B; Cırık DA; Yılmaz S; Tekin OM
    Taiwan J Obstet Gynecol; 2019 Mar; 58(2):234-238. PubMed ID: 30910145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs.
    Lin H; Li Y; Li L; Wang W; Yang D; Zhang Q
    PLoS One; 2014; 9(3):e91796. PubMed ID: 24642641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ratio of exogenous Luteinizing hormone to Follicle stimulating hormone administered for controlled ovarian stimulation is associated with oocytes' number and competence.
    Albu D; Albu A
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31850491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.